Biohaven Ltd. (NYSE:BHVN) Stock Has Average Price Target of $19.25

Biohaven Ltd. (NYSE:BHVN) has been assigned an average recommendation of “Moderate Buy” from the sixteen brokerages that are currently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, four have given a hold recommendation, eight have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $20.80.

BHVN has been the topic of several recent research reports. Morgan Stanley raised their target price on shares of Biohaven from $19.00 to $21.00 and gave the stock an “overweight” rating in a report on Tuesday. Wall Street Zen lowered Biohaven from a “hold” rating to a “sell” rating in a report on Saturday. Canaccord Genuity Group raised their price target on shares of Biohaven from $21.00 to $32.00 and gave the stock a “buy” rating in a report on Friday, October 30th. Robert W. Baird set a $48.00 target price on Biohaven in a research report on Thursday, October 22nd. Finally, Citigroup restated a “buy” rating on shares of Biohaven in a research note on Friday, September 18th.

Biohaven Stock Up 3.8%

Shares of BHVN stock opened at $14.42 on Monday. The company has a current ratio of 3.05, a quick ratio of 3.05 and a debt-to-equity ratio of 21.23. The stock has a market cap of $2.18 billion, a P/E ratio of -3.74 and a beta of 1.36. The company has a 50 day simple moving average of $13.61 and a two-hundred day simple moving average of $12.31. Biohaven has a 12 month low of $7.48 and a 12 month high of $18.24.

Biohaven (NYSE:BHVN) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.15). On average, research analysts expect that Biohaven will post -3.05 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. grew its position in Biohaven by 107.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 150,112 shares of the company’s stock valued at $2,004,000 after purchasing an additional 77,890 shares during the period. Commonwealth Equity Services LLC acquired a new position in shares of Biohaven during the 3rd quarter worth approximately $135,000. Profund Advisors LLC raised its holdings in Biohaven by 5.6% in the third quarter. Profund Advisors LLC now owns 57,036 shares of the company’s stock valued at $761,000 after acquiring an additional 3,018 shares in the last quarter. Sigma Planning Corp raised its stake in shares of Biohaven by 43.1% during the 3rd quarter. Sigma Planning Corp now owns 19,944 shares of the company’s stock worth $266,000 after buying an additional 6,008 shares during the last quarter. Finally, Sterling Capital Management LLC raised its stake in shares of Biohaven by 847.5% in the 3rd quarter. Sterling Capital Management LLC now owns 4,444 shares of the company’s stock valued at $59,000 after purchasing an additional 3,975 shares in the last quarter. Institutional investors own 88.78% of the company’s stock.

More Biohaven News

Here are the key news stories impacting Biohaven this week:

• Positive Sentiment: Biohaven says a pivotal Phase 3 trial of BHV-1300 for Graves’ disease is underway and presented three research posters at the American Thyroid Association meeting. The program could address a disease with few recent treatment advances, though trial progress is not a guarantee of success. Biohaven Graves’ disease Phase 3 and ATA announcement
• Positive Sentiment: HC Wainwright raised several future EPS estimates, including narrowing its projected losses for 2026–2029 and forecasting positive EPS in 2030. These revisions may bolster expectations for longer-term financial improvement.
• Positive Sentiment: A separate report says a Morgan Stanley analyst expects BHVN shares to rise, adding a favorable analyst signal; the article headline does not provide the rationale or target. Morgan Stanley analyst outlook
• Negative Sentiment: Despite its improved forecasts, HC Wainwright maintained a Neutral rating and a $10 price target, below the recent share price—suggesting that the analyst sees downside relative to current levels.

About Biohaven

Biohaven Ltd. (NYSE:BHVN) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for neurological and neuropsychiatric diseases, as well as certain immunological and rare disorders. The company’s research activities include small-molecule medicines, monoclonal antibodies and other innovative therapeutic approaches.

Biohaven’s pipeline has included investigational treatments for conditions such as migraine, obsessive-compulsive disorder, spinal muscular atrophy, amyotrophic lateral sclerosis, mood disorders and autoimmune diseases.